Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR2B | P41595 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095724 | 1.00 | HTR2C (0.54) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL20095707 | 1.00 | HTR2C (0.54) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL20096265 | 1.00 | HTR2C (0.54) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL20095961 | 1.00 | HTR2C (0.54) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL20095708 | 1.00 | HTR2C (0.54) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL21311631 | 0.92 | HTR2C (0.44) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL23639074 | 0.90 | HTR2C (0.52) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL21311693 | 0.90 | HTR2C (0.52) | HTR2CHTR2AHTR2BHRH3DRD2 | |
| SCHEMBL21311629 | 0.84 | HTR1A (0.38) | HTR2CHTR2AHTR2BHRH3HTR1A | |
| SCHEMBL20095849 | 0.84 | MGLL (0.42) | HTR2CHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | HTR2C 1243/4885HTR2A 2222/4885HTR2B 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.